MA71734A - Composés pour le traitement du cancer - Google Patents

Composés pour le traitement du cancer

Info

Publication number
MA71734A
MA71734A MA71734A MA71734A MA71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A
Authority
MA
Morocco
Prior art keywords
cancer
compounds
treatment
Prior art date
Application number
MA71734A
Other languages
English (en)
Inventor
Advait Nagle
Nicholas Simon Stock
Wojciech Piotr SWIDERSKI
Evan Nathaniel Feinberg
Ben SKLAROFF
Brandon REINUS
Indrawan MCALPINE
Martin INDARTE
Christopher P. BURKE
Joe Fred NAGAMIZO
Alexis VAN VENROOY
Original Assignee
Genesis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Therapeutics, Inc. filed Critical Genesis Therapeutics, Inc.
Publication of MA71734A publication Critical patent/MA71734A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71734A 2022-09-13 2023-09-11 Composés pour le traitement du cancer MA71734A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263406081P 2022-09-13 2022-09-13
US202263419451P 2022-10-26 2022-10-26
US202263435170P 2022-12-23 2022-12-23
US202363536249P 2023-09-01 2023-09-01
EP23783180.5A EP4568948A1 (fr) 2022-09-13 2023-09-11 Composés pour le traitement du cancer
PCT/US2023/032420 WO2024059010A1 (fr) 2022-09-13 2023-09-11 Composés pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA71734A true MA71734A (fr) 2025-05-30

Family

ID=88237760

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71734A MA71734A (fr) 2022-09-13 2023-09-11 Composés pour le traitement du cancer

Country Status (18)

Country Link
EP (1) EP4568948A1 (fr)
JP (1) JP2025530333A (fr)
KR (1) KR20250067170A (fr)
CN (1) CN120112518A (fr)
AU (1) AU2023342774A1 (fr)
CA (1) CA3264256A1 (fr)
CL (1) CL2025000672A1 (fr)
CO (1) CO2025003099A2 (fr)
CR (1) CR20250124A (fr)
DO (1) DOP2025000057A (fr)
GE (1) GEAP202516737A (fr)
IL (1) IL319513A (fr)
JO (1) JOP20250057A1 (fr)
MA (1) MA71734A (fr)
MX (1) MX2025002817A (fr)
PE (1) PE20251692A1 (fr)
TW (1) TW202426427A (fr)
WO (1) WO2024059010A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202854A1 (fr) 2024-03-27 2025-10-02 Pfizer Inc. Inhibiteurs de cdk4 et combinaisons avec des inhibiteurs de cdk2 ou d'autres agents destinés à être utilisés dans le traitement du cancer
WO2025240536A1 (fr) * 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante d'une cycline et/ou la kinase 4 dépendante d'une cycline par l'intermédiaire de la voie ubiquitine-protéasome
WO2026024674A1 (fr) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Méthodes de traitement de cancers associés à skp2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP13408A (en) * 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
IL295174B2 (en) 2020-01-29 2026-01-01 Foghorn Therapeutics Inc Compounds and their uses
WO2022105771A1 (fr) 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 Dérivé hétérocyclique azoté, son procédé de préparation et son application médicale
WO2022135365A1 (fr) * 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Inhibiteurs de kinase de cyclopentane disubstitués
WO2022174031A1 (fr) 2021-02-12 2022-08-18 Relay Therapeutics, Inc. Inhibiteurs de cdk et leurs procédés d'utilisation

Also Published As

Publication number Publication date
IL319513A (en) 2025-05-01
EP4568948A1 (fr) 2025-06-18
KR20250067170A (ko) 2025-05-14
CL2025000672A1 (es) 2025-07-11
AU2023342774A1 (en) 2025-02-27
JOP20250057A1 (ar) 2025-03-12
CA3264256A1 (fr) 2024-03-21
GEAP202516737A (en) 2025-06-10
JP2025530333A (ja) 2025-09-11
DOP2025000057A (es) 2025-04-08
WO2024059010A1 (fr) 2024-03-21
MX2025002817A (es) 2025-04-02
CR20250124A (es) 2025-05-07
CN120112518A (zh) 2025-06-06
PE20251692A1 (es) 2025-07-02
TW202426427A (zh) 2024-07-01
CO2025003099A2 (es) 2025-03-27

Similar Documents

Publication Publication Date Title
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA71734A (fr) Composés pour le traitement du cancer
MA71370A (fr) Inhibiteurs macrocycliques de kras pour le traitement du cancer
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
EP3935050A4 (fr) Composés hétérocycliques pour traitement médical
MA55325A (fr) Composés pour le traitement de maladies pd-l1
EP4467154A4 (fr) Médicament pour le traitement ou la prévention du cancer
MA71325A (fr) Inhibiteur de kras g12c pour le traitement du cancer
EP3968996A4 (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3986863A4 (fr) Inhibiteurs de glycolate oxydase pour le traitement d'une maladie
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
MA51738A (fr) Composés pour le traitement de la douleur
EP4373525A4 (fr) Combinaisons de traitement pour le cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3990458A4 (fr) Composés pour le traitement du cancer
EP3877382A4 (fr) Nouveaux composés pour le traitement de maladies respiratoires
EP4288059A4 (fr) Composés pour le traitement de l'ataxie spinocérébelleuse de type 3
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4209216A4 (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4251143A4 (fr) Composition de benzènesulfonamide pour le traitement du mélanome
EP3793548A4 (fr) Composés pour le traitement du cancer du pancréas
EP3849544A4 (fr) Polythérapie pour le traitement du cancer de la prostate
EP4121403A4 (fr) Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus